Ethaselen (BBSKE) is an orally bioavailable, selective inhibitor of thioredoxin reductase 1 (TrxR1). It demonstrates anticancer activity by inducing apoptosis and inhibiting proliferation, particularly in colorectal cancer models, and shows synergistic effects when combined with oxaliplatin in both in vitro and in vivo studies.
